MK-677 vs Ipamorelin: Oral vs Injectable GH

MK-677 vs Ipamorelin: Oral vs Injectable GH MK-677 vs ipamorelin: oral ghrelin mimetic (24h half-life, 25-27% glucose rise) vs injectable selective GHRP. Trial data and cost. You are choosing between a pill and a syringe. MK-677 (ibutamoren) is an oral, non-peptide ghrelin mimetic with a 24-hour half-life. Ipamorelin is an injectable pentapeptide with a 2-hour half-life. Both raise growth hormone, but ipamorelin does so without affecting cortisol, prolactin, or fasting glucose, while MK-677 raises fasting glucose by 25-27% within 2-4 weeks and one clinical trial was stopped early for congestive heart failure concerns (Nass et al., J Clin Endocrinol Metab, 2008; Raun et al., Endocrinology, 1998). MK-677's key advantage is oral dosing; ipamorelin's key advantage is safety. Administration Oral (capsule/liquid) Subcutaneous injection Half-life ~24 hours ~2 hours Receptor target Ghrelin receptor (full agonist) Ghrelin receptor (selective agonist) Cortisol effect None documented None (even at 200x dose) Prolactin effect None Insulin resistance Significant (25-27% glucose increase) None at therapeutic doses Appetite increase Significant, persistent Mild Water retention 40% of subjects in trials 15-25% Monthly cost $30-80 (research-grade) $150-300 (compounded) FDA status Not approved For ipamorelin dosing protocols, use our CJC-1295/ipamorelin dosage calculator. Neither compound is FDA-approved for human therapeutic use. Consult a healthcare provider before use. Do not use MK-677 if you have prediabetes, diabetes, or insulin resistance. Tailored to your body and goals Precise dosing and cycle length Safe stacking combinations Backed by peer-reviewed studies Ready in under 2 minutes MK-677 is a non-peptide, orally active ghrelin mimetic originally developed by Merck. It binds the ghrelin receptor (GHS-R1a) and stimulates growth hormone release from the pituitary gland. A single 25 mg oral dose sustains elevated GH and IGF-1 for a full 24 hours. It is not a peptide. It is not a SARM, despite frequent mislabeling on supplement websites. MK-677 is a small molecule with oral bioavailability above 60% (Murphy et al., J Clin Endocrinol Metab, 1998). In healthy elderly subjects, 25 mg/day for 4 weeks restored IGF-1 levels to the range of young adults, a 40-60% increase from baseline (Chapman et al., J Clin Endocrinol Metab, 1996). A 12-month randomized controlled trial confirmed sustained fat-free mass increases but documented insulin resistance as the primary safety concern (Nass et al., 2008). Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that earned the title "first selective growth hormone secretagogue" in the landmark Raun et al. study. It stimulates GH release through the ghrelin receptor, but with a selectivity profile unlike any other compound in its class. At doses up to 200 times the effective threshold, ipamorelin does not elevate cortisol, ACTH, prolactin, FSH, LH, or TSH (Raun et al., Endocrinology, 1998). No other GH secretagogue achieves this level of selectivity. This is not marketing language; it is the defining result of a preclinical study that distinguished ipamorelin from every compound that came before it. Its half-life is approximately 2 hours, with a GH peak at about 40 minutes post-injection and dose-proportional pharmacokinetics (Johansen et al., Eur J Clin Pharmacol, 1999). Standard dosing is 100-300 mcg subcutaneously, typically paired with CJC-1295 for synergistic GHRH-GHRP activation. Both compounds target the ghrelin receptor on the pituitary gland. The difference lies in activation pattern, duration, and downstream effects. MK-677 acts as a full agonist at GHS-R1a, the same receptor that endogenous ghrelin uses. Because ghrelin is the hunger hormone, MK-677 activates the appetite signaling cascade alongside GH release. The 24-hour half-life means this activation persists around the clock. Think of it like leaving a faucet on all day. GH flows steadily, but so does the hunger signal and the metabolic strain. Ghrelin receptor activation for 24 continuous hours is a fundamentally different stimulus than the body's natural pulsatile GH secretion pattern, which releases GH in discrete pulses with near-zero baseline between them. Ipamorelin binds the same receptor but triggers a narrower downstream cascade. GH is released. Cortisol, ACTH, and prolactin are not affected. Appetite stimulation is minimal compared to MK-677 or GHRP-6. The 2-hour half-life produces a discrete GH pulse that clears quickly, mimicking the body's natural secretory rhythm. This pulsatile pattern is closer to physiological GH release than MK-677's sustained elevation. When paired with CJC-1295 (a GHRH analog), ipamorelin activates two complementary pathways for synergistic GH output. For the full stack analysis, see CJC-1295/ipamorelin benefits. Both compounds raise GH and IGF-1 meaningfully. The pattern and duration differ. MK-677 at 25 mg/day restored IGF-1 in elderly subjects to levels matching young adults (40-60% increase from baseline) within 2 weeks. After 12 months of continuous use, IGF-1 remained elevated and fat-free mass increased significantly by DXA scan (Nass et al., 2008). In obese subjects, 2 months of MK-677 increased fat-free mass and basal energy expenditure (Murphy et al., 1998). Ipamorelin produces dose-proportional GH peaks at approximately 40 minutes post-injection. The GH pulse is sharp and resolves within 4-6 hours. Direct body composition studies for ipamorelin alone are limited; most clinical data uses ipamorelin combined with CJC-1295. IGF-1 elevation 40-60% increase, sustained 24h Pulsatile, returns to baseline within hours GH peak timing Gradual rise over 2-6 hours Sharp peak at ~40 minutes GH duration 24 hours (continuous) 4-6 hours (pulsatile) Body composition data 12-month RCT (DXA confirmed) Limited standalone data GH pattern Sustained elevation Pulsatile (more physiological) This is where the two compounds diverge most sharply. MK-677 carries metabolic risks that ipamorelin does not. The Nass 2008 randomized controlled trial documented fasting glucose increases of 25-27% within 2-4 weeks of MK-677 use. In 6% of subjects, fasting glucose exceeded 140 mg/dL. HbA1c rose by 0.3% on average over 12 months. One clinical trial in elderly patients recovering from hip fractures was stopped early due to congestive heart failure concerns in the MK-677 group (Nass et al., 2008). Water retention affected 40% of subjects. Arthralgias (joint pain) appeared in 20%. Carpal tunnel symptoms developed in 10%. Appetite increase is significant and typically persists for the duration of use. Insulin resistance/glucose increase Very common (25-27% rise) Moderate-Severe Increased appetite Very common Moderate, persistent Water retention/edema 40% Mild-Moderate Arthralgias 20% Carpal tunnel symptoms 10% Lethargy Common These are not theoretical risks from animal models. The glucose and insulin data come from multiple randomized controlled trials with up to 12-month follow-up. Ipamorelin's side effect profile at therapeutic doses consists of injection site reactions, transient flushing, and occasional light-headedness. No cortisol elevation has been detected even at doses 200 times the effective threshold (Raun et al., 1998). No significant appetite spike. No insulin resistance at standard doses. No edema at the rates seen with MK-677. The trade-off: you need a syringe, bacteriostatic water, and injection supplies. For complete side effect management, see our CJC-1295/ipamorelin side effects guide. Injection site reactions 20-30% Facial flushing 15-20% Mild, transient Light-headedness 5-10% Cortisol increase None (at any dose) N/A Minimal Scenario 1: You take MK-677 at 25 mg/day without glucose monitoring. After 3 weeks, your fasting glucose rises from 90 mg/dL to 115 mg/dL. That is the prediabetic range. If your baseline was already 100 mg/dL, MK-677 could push you to 125-127 mg/dL, past the diabetic diagnostic threshold. Scenario 2: You inject ipamorelin at 200 mcg before bed. GH peaks during your deep sleep cycle. Your fasting glucose the next morning is unchanged from baseline. No appetite disruption affects your diet. The full cost of this safety advantage: one subcutaneous injection with a 30-gauge needle, 30 seconds, every day. The safety gap between these compounds is not subtle. For comprehensive comparison of GH peptide risks, see our peptide safety guide. Both compounds are commonly used for sleep improvement. MK-677 has a specific advantage here. Copinschi et al. (1997) administered MK-677 to young men and documented a 50% increase in Stage IV (deep) sleep duration and a 20% increase in REM sleep. Total sleep time did not change, but the quality shifted toward more restorative stages (Copinschi et al., Neuroendocrinology, 1997). Ipamorelin lacks a dedicated sleep study. Users commonly report improved sleep quality, deeper rest, and vivid dreams, consistent with GH-mediated sleep enhancement. The mechanism is sound: GH secretion naturally peaks during deep sleep, and ipamorelin before bed amplifies this pulse. Stage IV sleep +50% (RCT data) Improved (clinical reports) REM sleep +20% (RCT data) Evidence level PubMed RCT User reports + GH physiology Timing Once daily oral Before bed subcutaneous For documented sleep enhancement, MK-677 has stronger published evidence. For sleep improvement without metabolic risk, ipamorelin before bed is the conservative choice. For a broader review of sleep-targeting peptides, see our peptides for sleep guide. MK-677 has the most direct body composition evidence among non-prescription GH secretagogues. The Nass 2008 twelve-month study used DXA in healthy elderly subjects. MK-677 at 25 mg/day produced statistically significant increases in fat-free mass. Limb fat also increased. Total body weight rose, partly from water retention and lean tissue. Grip strength and physical function did not improve despite the body composition changes. In obese subjects, Murphy et al. (1998) documented increased fat-free mass and basal metabolic rate after 2 months. Higher lean mass combined with higher energy expenditure is favorable for recomposition, though insulin resistance complicates long-term use. Ipamorelin standalone body composition data is limited. The CJC-1295/ipamorelin combination is the standard clinical protocol, and practitioners report improvements in fat loss, recovery, and lean tissue over 8-12 week cycles. For a broader comparison including FDA-approved options for fat loss, see best peptides for weight loss. Fat-free mass Increased (DXA confirmed) Strength No improvement No direct data Energy expenditure Increased (obese subjects) Body composition format MK-677 alone Best data is with CJC-1295 MK-677 is cheaper and more convenient. This explains its popularity despite the metabolic risks. Oral capsule or liquid Supplies needed Syringes, bacteriostatic water, alcohol swabs Storage Room temperature (capsules) Refrigerated after reconstitution Preparation time Seconds (swallow capsule) 5-10 minutes (reconstitute, draw, inject) MK-677 requires zero injection supplies and no reconstitution. For people with needle aversion, this is a decisive advantage. Ipamorelin requires purchasing bacteriostatic water, insulin syringes, and the peptide vial, then reconstituting and injecting subcutaneously 1-3 times daily. Use our peptide reconstitution calculator for guidance on ipamorelin preparation. Both compounds are research chemicals without FDA approval. MK-677 is sometimes mislabeled and sold as a dietary supplement. The FDA has issued warnings against such products. Ipamorelin is available through compounding pharmacies with a valid prescription. The decision framework is clear once you weigh metabolic risk against convenience. You are needle-averse and oral dosing is essential. Sleep improvement is your primary goal and you want the compound with clinical sleep data (Copinschi 1997). Your fasting glucose is below 90 mg/dL, HbA1c is under 5.4%, and you have no family history of type 2 diabetes. You plan short-term use (8-12 weeks maximum) with glucose monitoring at baseline and week 4. Budget is a meaningful constraint. Selectivity and safety are your priorities. You have any insulin resistance risk factors: fasting glucose above 95 mg/dL, HbA1c above 5.5%, family history of diabetes, BMI above 30, or existing cardiovascular risk. You want to stack with CJC-1295 for synergistic GHRH-GHRP activation. You prefer pulsatile, physiological GH release. You plan long-term cycling over multiple months. For the three-way comparison including tesamorelin and sermorelin, see our tesamorelin vs sermorelin vs ipamorelin guide. For bodybuilding context, see peptides for bodybuilding. Stacking MK-677 with ipamorelin is not recommended. Both target the ghrelin receptor, creating pharmacological redundancy rather than synergy. You double the ghrelin pathway stimulation without adding a complementary mechanism. Additive appetite stimulation and water retention would be pronounced. Insulin resistance risk from MK-677 would persist regardless of stacking. Better stacks activate two distinct receptor pathways. Ipamorelin pairs with CJC-1295 (a GHRH analog that activates the GHRH receptor) for genuine synergy: the GHRH analog tells the pituitary to produce GH, while ipamorelin tells it to release GH. MK-677 is best used alone. For comprehensive stacking guidance, see our peptide stacking guide. Both compounds require monitoring, but MK-677 demands more frequent glucose checks. Baseline Fasting glucose, HbA1c, IGF-1, fasting insulin IGF-1, fasting glucose, CMP Week 4 Fasting glucose, fasting insulin (critical) IGF-1 (optional) Week 8-12 Full panel: glucose, HbA1c, IGF-1, CMP IGF-1, fasting glucose Post-cycle (4 weeks off) Fasting glucose, IGF-1 IGF-1 Stop MK-677 immediately if: fasting glucose exceeds 126 mg/dL on two consecutive readings, fasting insulin doubles from baseline, or lower extremity edema develops and does not resolve with hydration and sodium reduction. Stop ipamorelin if: severe persistent headaches develop, joint pain limits daily function, or IGF-1 exceeds the upper reference range for your age. For comprehensive safety protocols, see our peptide safety guide. Neither MK-677 nor ipamorelin is FDA-approved for any indication. All human data comes from Phase I/II clinical trials and observational reports. MK-677 carries specific risks that cannot be understated. A randomized trial in elderly hip fracture patients was stopped early because MK-677 subjects showed signs of congestive heart failure. The glucose and insulin sensitivity effects are documented across multiple studies and are not theoretical. Do not use MK-677 if you have type 2 diabetes, prediabetes, or poorly controlled fasting glucose. Do not use either compound if you have active cancer or a history of hormone-sensitive cancers without oncologist clearance. IGF-1 elevation may theoretically promote tumor growth. For recovery-focused peptide comparisons, see our peptides for recovery guide. For muscle growth context, see peptides for muscle growth. MK-677 produces more sustained GH and IGF-1 elevation over 24 hours. Ipamorelin produces sharper, shorter GH pulses. In total daily GH output, MK-677 at 25 mg/day likely exceeds ipamorelin at 200-300 mcg. But the sustained elevation comes with documented insulin resistance (25-27% glucose increase) and one halted trial. Ipamorelin paired with CJC-1295 produces synergistic output without those metabolic risks. MK-677 does not directly cause diabetes, but it raises fasting glucose by 25-27% within 2-4 weeks. In the Nass 2008 study, 6% of subjects exceeded 140 mg/dL fasting glucose. If your baseline is already elevated (above 95 mg/dL), MK-677 can push you into prediabetic or diabetic range. Monitor glucose at baseline and week 4. Do not use MK-677 if you have prediabetes. Yes. MK-677 is one of very few GH-stimulating compounds with oral bioavailability above 60%. It is taken as a capsule or liquid once daily. This is its primary practical advantage over injectable peptides like ipamorelin, which require subcutaneous injection, reconstitution, and injection supplies. The oral route does not reduce the metabolic side effect risk. Ipamorelin causes minimal appetite stimulation compared to MK-677 or GHRP-6. While it acts on the ghrelin receptor, its selective activation profile spares the aggressive hunger signaling seen with full ghrelin mimetics. Most users report little to no appetite change at 200-300 mcg doses, in contrast to MK-677's significant and persistent appetite increase. See the ipamorelin profile for mechanism details. MK-677 has clinical evidence for sleep improvement: Copinschi et al. (1997) documented a 50% increase in Stage IV deep sleep and 20% increase in REM sleep. Ipamorelin improves sleep through GH-mediated mechanisms but lacks a dedicated sleep study. For documented sleep enhancement, MK-677 has stronger evidence. For sleep improvement without metabolic risk, ipamorelin before bed is safer. See our peptides for sleep guide for full context. Ipamorelin is safer by every available metric. It does not raise cortisol, prolactin, or glucose at any tested dose. MK-677 raises fasting glucose by 25-27%, causes edema in 40% of users, and one trial was halted for heart failure concerns. The trade-off: ipamorelin requires injection, while MK-677 is oral. See our peptide safety guide for comprehensive risk assessment. Not recommended. Both target the ghrelin receptor, making the combination pharmacologically redundant. The additive appetite stimulation and water retention outweigh any theoretical GH benefit. Ipamorelin pairs better with CJC-1295 (a GHRH analog), which activates the complementary GHRH receptor pathway for true synergy. See our peptide stacking guide for productive GH secretagogue stack protocols. No. MK-677 is frequently mislabeled as a SARM on supplement websites, but it is a non-peptide ghrelin receptor agonist. It does not bind androgen receptors and has no direct anabolic effect on muscle tissue. Its body composition e MK-677 offers oral convenience, clinical sleep data, and documented body composition effects over 12 months. Ipamorelin offers the cleanest GH release profile ever documented: no cortisol, no prolactin, no glucose disruption at any tested dose. The safety gap between them is substantial and quantified in clinical literature. If you have no insulin sensitivity risk factors, need oral dosing, and plan short-term use with careful glucose monitoring, MK-677 is a reasonable choice. If you want the safest long-term GH secretagogue protocol with the cleanest side effect profile, ipamorelin paired with CJC-1295 is the standard. Use our CJC-1295/ipamorelin dosage calculator to build your protocol. For reconstitution help, see our peptide reconstitution calculator. For the broader GH peptide landscape, see our tesamorelin vs sermorelin vs ipamorelin three-way comparison.